The role of procalcitonin as a biomarker for acute pulmonary exacerbation in subjects with cystic fibrosis and non-cystic fibrosis bronchiectasis
Objective: Patients with cystic fibrosis (CF) and non-CF bronchiectasis are prone to exacerbations of pulmonary infections. C-reactive protein (CRP) and procalcitonin (PCT) are inflammatory markers. The aim of this study is to evaluate the role of CRP and PCT on exacerbations of CF and non-CF bronchiectasis. Patients and Methods: The medical records of 18 CF (52 hospitalizations) and 20 non-CF bronchiectasis patients (51 hospitalizations) were reviewed retrospectively. CRP, PCT levels and, white blood cell (WBC) counts on admission and follow-up were evaluated. Results: C-reactive protein levels correlated with PCT levels on admission in all patients. Baseline PCT levels were markedly higher (>0.5µg/L) in 12% of CF and 10% of non-CF bronchiectasis patients, however, baseline CRP values were markedly higher (>5mg/L) in 96% of CF and non-CF bronchiectasis patients (p=0.760 and p=0.100, respectively). Baseline CRP and PCT levels were positively correlated with hospitalization length (r=0.501, p=0.001 and r=0.289, p=0.04, respectively) in CF patients, but not in non-CF bronchiectasis. Conclusion: Our study shows the potential utility of these biomarkers to determine the severity of the exacerbation particularly predicting hospitalization length in CF patients. Both biomarkers could be able to guide antibiotic treatment of infective exacerbations in CF and non-CF bronchiectasis patients
___
- [1] Chmiel JF, Berger M, Konstan MW. The role of inflammation
in the pathophysiology of CF lung disease. Clin Rev Allergy
Immunol 2002; 23: 5-27. doi: 10.1385/CRIAI:23:1:005
- [2] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and
management of pulmonary infections in cystic fibrosis. Am
J Respir Crit Care Med 2003; 168: 918-51. doi: 10.1164/
rccm.200304-505SO
- [3] Waters V, Ratjen F. Standard versus biofilm antimicrobial
susceptibility testing to guide antibiotic therapy in cystic
fibrosis. Cochrane Database Syst Rev 2012; 11: CD009528.
doi: 10.1002/14651858.CD009528.pub2
- [4] Hsieh MH, Fang YF, Chen GY, et al. The role of the highsensitivity C-reactive protein in patients with stable noncystic fibrosis bronchiectasis. Pulm Med 2013; 2013: 795140.
doi: 10.1155/2013/795140
- [5] Briel M, Christ-Crain M, Young J, et al. Procalcitoninguided antibiotic
use versus a standard approach for acute
respiratory tract infections in primary care: study protocol for
a randomised controlled trial and baseline characteristics of
participating general practitioners [ISRCTN73182671]. BMC
Fam Pract 2005; 6: 34. doi: 10.1186/1471-2296-6-34
- [6] Glass S, Hayward C, Govan JR. Serum C-reactive protein in
assessment of pulmonary exacerbations and antimicrobial
therapy in cystic fibrosis. J Pediatr 1988; 113(1 Pt 1): 76-9. doi:
10.1016/s0022-3476(88)80533-x
- [7] Friesen CA, Wiens LA, Burry VF, Portnoy J, Roberts CC.
C-reactive protein in acute pulmonary exacerbations of
patients with cystic fibrosis. Pediatr Pulmonol 1995; 20: 215-
9. doi: 10.1002/ppul.195.020.0403
- [8] Christ-Crain M, Muller B. Procalcitonin in bacterial
infections—hype, hope, more or less? Swiss Med Wkly 2005;
135(31-32): 451-60. doi: 2005/31/smw-11169
- [9] Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum
procalcitonin and C-reactive protein levels as markers of
bacterial infection: a systematic review and meta-analysis.
Clin Infect Dis 2004; 39: 206-17. doi: 10.1086/421997
- [10] Gilbert DN. Procalcitonin as a biomarker in respiratory tract
infection. Clin Infect Dis 2011; 52 Suppl 4: S346-50. doi:
10.1093/cid/cir050
- [11] Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to
initiate or discontinue antibiotics in acute respiratory tract
infections. Cochrane Database Syst Rev 2012: CD007498. doi:
10.1002/14651858.CD007498.pub2
- [12] Louw JJ, Toelen J, Proesmans M, et al. Serum procalcitonin
is not an early marker of pulmonary exacerbation in children
with cystic fibrosis. Eur J Pediatr 2012; 171: 139-42. doi:
10.1007/s00431.011.1502-x
- [13] Roderfeld M, Rath T, Schulz R, et al. Serum matrix
metalloproteinases in adult CF patients: Relation to
pulmonary exacerbation. J Cyst Fibros 2009; 8: 338-47. doi:
10.1016/j.jcf.2009.06.001
- [14] Polverino E, Goeminne PC, McDonnell MJ, et al. European
Respiratory Society guidelines for the management of
adult bronchiectasis. Eur Respir J 2017; 50: 1700629 . doi:
10.1183/13993.003.00629-2017
- [15] Loebinger MR, Shoemark A, Berry M, Kemp M, Wilson
R. Procalcitonin in stable and unstable patients with
bronchiectasis. Chron Respir Dis 2008; 5: 155-60. doi:
10.1177/147.997.2308088823
- [16] Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of
aerosolized recombinant human DNase on exacerbations of
respiratory symptoms and on pulmonary function in patients
with cystic fibrosis. The Pulmozyme Study Group. N Engl J
Med 1994; 331: 637-42. doi: 10.1056/NEJM199.409.083311003
- [17] Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation
in adults with bronchiectasis: a consensus definition for clinical
research. Eur Respir J 2017; 49. doi: 10.1183/13993.003.00051-
2017
- [18] Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria
and exacerbations of chronic obstructive pulmonary disease.
N Engl J Med 2002; 347: 465-71. doi: 10.1056/NEJMoa012561
- [19] Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin
guidance of antibiotic therapy in community-acquired
pneumonia: a randomized trial. Am J Respir Crit Care Med
2006; 174: 84-93. doi: 10.1164/rccm.200.512.1922OC
- [20] Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment
of exacerbations of COPD: a randomized, controlled trial
comparing procalcitonin-guidance with standard therapy.
Chest 2007; 131: 9-19. doi: 10.1378/chest.06-1500
- [21] Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon
BS. Systematic review of blood biomarkers in cystic fibrosis
pulmonary exacerbations. Chest 2013; 14: 1659-1670. doi:
10.1378/chest.13-0693
- [22] Horsley AR, Davies JC, Gray RD, et al. Changes in physiological,
functional and structural markers of cystic fibrosis lung
disease with treatment of a pulmonary exacerbation. Thorax
2013; 68: 532-9. doi: 10.1136/thoraxjnl-2012-202538
- [23] Loh G, Ryaboy I, Skabelund A, French A. Procalcitonin,
erythrocyte sedimentation rate and C-reactive protein in
acute pulmonary exacerbations of cystic fibrosis. Clin Respir J
2018; 12(4): 1545-1549. doi: 10.1111/crj.12703
- [24] Bailey KL, Murphy PJ, Lineberry OK, et al. Procalcitonin
predicts the severity of cystic fibrosis pulmonary exacerbations
and readmissions in adult patients: a prospective cohort study.
J Investig Med 2020; 68: 856-863. doi: 10.1136/jim-2019-
001183
- [25] Sequeiros IM, Jarad NA. Extending the course of intravenous
antibiotics in adult patients with cystic fibrosis with acute
pulmonary exacerbations. Chron Respir Dis 2012; 9: 213-20.
doi: 10.1177/147.997.2312445903
- [26] Ito A, Ishida T, Tachibana H, Ito Y, Takaiwa T. Serial
procalcitonin levels for predicting prognosis in communityacquired pneumonia. Respirology
2016; 21: 1459-64. doi: 10.1111/resp.12846